IP Verse

Brand patent opposition analysis

The comprehensive analysis of Brand opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Latest patent oppositions filed by Brand

Stay updated with the latest patent oppositions filed by Brand

Patent NumberTitleApplicantOpposition DateOpposition Company
EP3858859
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 28, 2026BRAND MURRAY FULLER
EP4188389
Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECAJun 16, 2026BRAND MURRAY FULLER
EP4385509
Migalastat Formulations Having Improved PharmacokineticsAMICUS THERAPEUTICSJun 3, 2026BRAND MURRAY FULLER
EP4512389
Degarelix Drug ProductFERRINGJun 1, 2026ACCORD HEALTHCARE SLU
EP3689365
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKMay 5, 2026ZENTIVA
EP4374918
Methods Of Treating Fabry Patients Having Renal ImpairmentAMICUS THERAPEUTICSApr 15, 2026BRAND MURRAY FULLER
EP4403228
Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHEApr 8, 2026BRAND MURRAY FULLER
EP4188327
Combination Therapy For Inhalation AdministrationCHEMO RESEARCHFeb 26, 2026BRAND MURRAY FULLER
EP3756650
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEJan 12, 2026BRAND MURRAY FULLER
EP3470400
Crystal Form Of Ozanimod, Crystal Form Of Hydrochloride Thereof, And Preparation Method ThereforRECEPTOSJan 2, 2026BRAND MURRAY FULLER

Top clients of Brand

Top companies who are the clients of Brand

CompanyTotal
BRAND MURRAY FULLER32
ACCORD HEALTHCARE10
STRAWMAN6
ADALVO3
GLENMARK PHARMACEUTICALS EUROPE2
INNOVIA FILMS2
INTAS PHARMACEUTICALS2
TROY CHEMICAL1
ZENTIVA1
MARKS & CLERK1